drugset / Trial / NCT06702332
Single Ascending Dose Study of MSD-001 in Healthy Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this Phase 1 single ascending dose (SAD) study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamic profile of MSD-001 when administered orally to healthy adult participants.
Timeline
- Start
- 2024-11-11
- Primary completion
- 2025-06-19
- Completion
- 2025-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MSD-001 | Unknown | — | Oral |